2025 AHA CME Symposium - Exploring the Evidence: GLP-1 RAs in Individuals with T2D and ASCVD
Jersey Desk/10313499

HAZLET, N.J. - JerseyDesk -- In this symposium, an expert faculty will discuss the data with injectable GLP-1 RAs in ASCVD patients and the place of injectable GLP-1 RAs in reduction of cardiovascular risk. The design, efficacy and safety results from the SOUL trial will be presented, as well as the latest meta-analyses with GLP-1 RAs. Cases of patients with T2D and ASCVD will be presented, and attendees will be provided with best practices incorporating evidence-based clinical decision making and patient-centered care.

Click here for more information

CHAIR

Darren McGuire, MD MHSC
Distinguished Chair in Cardiovascular Science
Distinguished Teaching Professor

More on Jersey Desk

• Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
• FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
• Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
• Anna D. Banks Featured as Panelist at Women, Wealth & Wisdom Empowerment Brunch
• Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany

University of Texas Southwestern Medical Center
Dallas, Texas

FACULTY

Lawrence Letter, MD, FRCPC
Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, Ontario, Canada

Neha Pagidipati, MD, MPH
Associate Professor of Medicine
Duke University School of Medicine
Durham, North Carolina

Richard Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
AdventHealth Translational Research Institute
Medical Director, AdventHealth Diabetes Institute
Orlando, Florida

Educational Objectives
- Describe the key injectable GLP-1 RA clinical trials and meta analyses in patients with T2D and high ASCVD risk
- Explain the American Diabetes Association 2025 guideline recommendations for the use of GLP-1 RAs in patients with T2D and ASCVD or multiple risk factors for ASCVD
- Interpret the evidence from the SOUL trial and describe the potential role for oral GLP-1 RA therapy in patients with T2D and high risk

Target Audience

More on Jersey Desk

• HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
• Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
• OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
• P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
• DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials

This program is intended for cardiovascular clinicians and other healthcare professionals who manage patients with T2D and ASCVD risk.

Educational Grant
Voxmedia International gratefully acknowledges the educational grant from Novo Nordisk Inc.

Accreditation and Credit Designation Statements
Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia, LLC designates this live activity for a maximum of 1.5 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.